Tango Therapeutics (TNGX) Stock Price, News & Analysis

Company Overview

Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. Founded in 2017, Tango is focused on harnessing the power of synthetic lethality to discover and develop precision oncology therapies. By identifying tumor-specific genetic dependencies, the company aims to create targeted treatments that exploit vulnerabilities unique to cancer cells while sparing healthy tissues.

The company’s proprietary discovery engine integrates CRISPR-based genome-wide screening with advanced computational biology to pinpoint novel synthetic lethal interactions. Tango’s pipeline includes multiple wholly owned programs targeting DNA damage repair pathways, as well as immuno-oncology and metabolic vulnerabilities. Lead assets are advancing through preclinical validation and into early-stage clinical trials, with several IND submissions anticipated in the coming years.

Tango has forged strategic collaborations with leading pharmaceutical partners to co-develop select programs and expand its therapeutic reach. These alliances leverage Tango’s expertise in target identification alongside partners’ clinical development and commercialization capabilities. The company is led by CEO Debora Barton, Ph.D., whose leadership team brings deep experience in oncology drug discovery, translational research and global biopharmaceutical operations.

Operating primarily in the United States, Tango maintains research and development facilities in Kendall Square and collaborates with academic institutions and contract research organizations worldwide. Committed to advancing next-generation cancer medicines, the company’s mission is to deliver differentiated therapies that offer new treatment options for patients with high unmet medical need across diverse tumor types.

Key Stats

• Today's Range: $6.36 to $6.85
• 50-Day Range: $1.29 to $6.86
• 52-Week Range: $1.03 to $12.02
• Volume: 1.80 million shs
• Average Volume: 1.62 million shs
• Market Capitalization: $724.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.50
• Consensus Rating: Buy

Tango Therapeutics Stock Analysis - MarketRank™

Tango Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 739th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tango Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.19) to ($1.38) per share.

Price to Book Value per Share Ratio

Tango Therapeutics has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

35.96% of the float of Tango Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tango Therapeutics has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Tango Therapeutics has recently increased by 35.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tango Therapeutics does not currently pay a dividend.

Dividend Growth

Tango Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

35.96% of the float of Tango Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tango Therapeutics has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Tango Therapeutics has recently increased by 35.23%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Tango Therapeutics this week, compared to 3 articles on an average week.

Search Interest

15 people have searched for TNGX on MarketBeat in the last 30 days. This is an increase of 275% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tango Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.50% of the stock of Tango Therapeutics is held by insiders.

Percentage Held by Institutions

78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TNGX Stock Analysis - Frequently Asked Questions

How have TNGX shares performed this year?

Tango Therapeutics' stock was trading at $3.09 at the beginning of 2025. Since then, TNGX shares have increased by 116.2% and is now trading at $6.68.

How were Tango Therapeutics' earnings last quarter?

Tango Therapeutics, Inc. (NASDAQ:TNGX) announced its quarterly earnings results on Monday, May, 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.02. The business earned $5.39 million during the quarter, compared to the consensus estimate of $6.73 million. Tango Therapeutics had a negative net margin of 322.67% and a negative trailing twelve-month return on equity of 62.75%.

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tango Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tango Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/22/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNGX
• CIK: 1819133
• Web: www.tangotx.com
• Phone: 857-320-4900
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tango Therapeutics: $10.50
• High Price Target: $13.00
• Low Price Target: $8.00
• Potential Upside/Downside: +58.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.30 million
• Net Margins: -322.67%
• Pretax Margin: -322.17%
• Return on Equity: -62.75%
• Return on Assets: -39.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.26
• Quick Ratio: 6.26

Sales & Book Value

• Annual Sales: $42.07 million
• Price / Sales: 17.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.86 per share
• Price / Book: 3.57

Miscellaneous

• Outstanding Shares: 108,390,000
• Free Float: 100,264,000
• Market Cap: $719.28 million
• Optionable: Optionable
• Beta: 1.63